BD8975153
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dionehemihydrate , 99+% , 847871-99-2
| Pack Size | Price | Stock | Quantity |
| 100mg | RMB979.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| storage temp. | Store at -20°C |
| solubility | DMSO : 50 mg/mL (186.38 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) |
| form | Powder |
| color | Off-white to pink |
| InChI | InChI=1S/2C13H13N3O3.H2O/c2*14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18;/h2*1-3,10H,4-6,14H2,(H,15,17,18);1H2 |
| InChIKey | OTJHSDXKMBRCMM-UHFFFAOYSA-N |
Description and Uses
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
